18 citations
,
August 2019 in “Clinical breast cancer” Local hormonal treatment for vulvovaginal atrophy is likely safe for women with estrogen receptor-positive breast cancer on aromatase inhibitors.
May 1993 in “Drugs & Therapy Perspectives” Formestane is a preferred second-line treatment for advanced breast cancer in postmenopausal women because it's effective and has fewer side effects.
April 2022 in “Reactions Weekly” May 2022 in “Reactions Weekly” 
110 citations
,
August 2015 in “Neuropsychopharmacology” High-dose dutasteride reduces PMDD symptoms by stabilizing neurosteroid levels.
December 2021 in “Research Square (Research Square)” Hair growth-promoting nutraceuticals do not block the cancer-fighting effects of tamoxifen and may enhance its action.
January 2025 in “Reactions Weekly” November 2024 in “Reactions Weekly” May 2023 in “Reactions Weekly” 
7 citations
,
September 2023 in “Cancer Treatment Reviews” Managing side effects of endocrine therapy is crucial to improve adherence and survival in breast cancer patients.
4 citations
,
January 1996 in “PubMed” July 2013 in “Revista da Universidade Vale do Rio Verde” Flutamide treatment showed no significant changes in mice vaginal mucosa.
65 citations
,
October 2008 in “Journal of Neuroendocrinology” 
February 2022 in “Research Square (Research Square)” Certain nutraceuticals may enhance hair growth without affecting the cancer-fighting properties of tamoxifen.
February 2024 in “PloS one” Nutraceuticals that promote hair growth do not reduce tamoxifen's effectiveness in breast cancer treatment.
2 citations
,
December 2013 in “Cancer research” Enobosarm may effectively treat androgen receptor-positive breast cancer with fewer side effects.
11 citations
,
March 2016 in “Translational Andrology and Urology” Nandrolone might increase muscle mass with fewer side effects than testosterone but could cause erectile dysfunction and needs more research.
May 2024 in “Reactions weekly” January 2018 in “Journal of analytical, bioanalytical and separation techniques” September 2021 in “Zenodo (CERN European Organization for Nuclear Research)” 
4 citations
,
January 2019 in “Dermatology Online Journal” Low-dose naltrexone might be a cheap and effective additional treatment for hair loss with scalp discomfort due to its anti-inflammatory effects and few side effects.
2 citations
,
May 2012 in “Indian drugs” Finasteride, a hair loss treatment, works better and is more stable when delivered through specially prepared gels, leading to increased hair growth.
8 citations
,
April 2020 in “Journal of The American Academy of Dermatology” Bicalutamide may be a promising alternative treatment for female pattern hair loss.
October 2020 in “System Dynamics Review” The document concludes that finasteride can reduce nandrolone detection in doping tests, suggesting frequent testing and setting metabolite level thresholds for detection.
10 citations
,
February 2008 in “International Journal of Andrology” A combination of nanomilled oral testosterone and dutasteride normalized testosterone levels in men with low testosterone and is safe for short-term use.
July 2025 in “Journal of Investigative Dermatology” 
February 2026 in “International Journal on Science and Technology” Vitex negundo may help treat PCOD, but more human studies are needed.
May 2008 in “Trends in Urology Gynaecology & Sexual Health” Loop diuretics may double bone loss in elderly men, finasteride lowers prostate cancer risk but may increase high-grade tumors, abarelix reduces testosterone quickly, and transdermal testosterone offers minimal sexual benefit for women.
April 2010 in “Nature Reviews Urology” 
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for treating prostate issues and hair loss without hormonal side effects.